Biologics for Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
In this slideshow, we review the biologics currently approved to treat adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Brodalumab Approved for Psoriasis
The U.S. Food and Drug Administration has approved brodalumab (Siliq) for the treatment of adults and moderate-to-severe plaque psoriasis.
Axial Disease and Psoriasis Increasingly Linked
Axial disease seems to increasingly depend on the presence of skin psoriasis and HLA-B*27 alleles, researchers write in ARD.
2016 Psoriasis Treatment Guidelines Issued
New treatment guidelines for plaque psoriasis have been issued in the U.S. where 50 percent of patients say they are dissatisfied with treatment.
Psoriasis Patients Require Annual PsA Screening
Up to 30% of psoriasis patients will develop psoriatic arthritis. Studies show that a proportion of patients in clinical care have undiagnosed PsA.
Increased Risk of Leukemia Associated with an Autoimmune Disease Treatment
Researchers reporting at the American Society of Hematology annual meeting this week say there is a link between a treatment for autoimmune disease and the development of leukemia.
Apremilast vs CF101 for Psoriasis
Researchers find that apremilast and CF101 both are safe and effective for psoriasis, but apremilast outperforms CF101 through 16 weeks, until it plateaus.
Adalimumab-atto: It’s Indications and Key Takeaways
In this slideshow, we summarize the newly approved indications for Amgen's new biosimilar, adalimumab-atto (Amjevita) and, we highlight key points as stated by Amgen researchers.
10 Points to Consider when Evaluating your PsA Patients
Some new and old concepts to consider when evaluating patients with severe psoriatic arthritis (PsA) for cardiovascular diseases.
By clicking Accept, you agree to become a member of the UBM Medica Community.